<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03951415</url>
  </required_header>
  <id_info>
    <org_study_id>DOMEC</org_study_id>
    <nct_id>NCT03951415</nct_id>
  </id_info>
  <brief_title>Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer</brief_title>
  <acronym>DOMEC</acronym>
  <official_title>Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DOMEC trial is designed as a Dutch Gynecological Oncology Group (DGOG), prospective,&#xD;
      multi-center, phase II study for 55 patients with advanced (recurrent, refractory or&#xD;
      metastatic) endometrial cancer or carcinosarcoma of the uterus to investigate the efficacy of&#xD;
      the combination therapy of olaparib tablets and durvalumab IV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prognosis of recurrent or persistent endometrial carcinoma not amenable to local therapy&#xD;
      is poor. First line therapy exists of platinum-based chemotherapy or hormonal therapy. No&#xD;
      standard subsequent-line therapy has been described.The combination of Poly(ADP-ribose)&#xD;
      polymerases (PARP) inhibition and Programmed death-ligand 1 (PD-L1) blocking has great&#xD;
      potential in the treatment of recurrent endometrial cancer. The DOMEC trial is designed to&#xD;
      investigate this treatment combination among all molecular subgroups.&#xD;
&#xD;
      The DOMEC trial is designed as a DGOG, prospective, multi-center, phase II study for 55&#xD;
      patients with advanced (recurrent, refractory or metastatic) endometrial cancer, including&#xD;
      carcinosarcoma of the uterus. Patients must have had one prior platinum-based&#xD;
      chemotherapeutic regimen or not be able/willing to get chemotherapy. The aim is to&#xD;
      investigate the efficacy of the combination therapy of olaparib tablets 300mg twice daily&#xD;
      orally and durvalumab 1500mg by IV infusion every 4 weeks in terms of progression free&#xD;
      survival. Secondary objectives are to investigate objective response rate, overall survival,&#xD;
      safety and predictive biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 8, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>6 months</time_frame>
    <description>PFS will be counted from the date of registration until the first observation of radiological progressive disease according to RECIST 1.1 criteria or death due to any cause, whichever occurred first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Through study completion, up to 36 months</time_frame>
    <description>OS will be determined from the date of registration until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Through study completion, up to 36 months</time_frame>
    <description>Assessed by NCI Common Terminology Criteria for adverse Events (CTCAE) version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive biomarkers in tumor biopsy</measure>
    <time_frame>At baseline</time_frame>
    <description>MMRd/POLE, HR status, quantification of CD3,CD4,CD8,CD103,CD161,PD-1,LAG3,CTLA-4,NKG2A,GOXp3 positieve T cells, NK cells, percentage PD-L1 on myeloid cells/tumorcells, quantification of myeloid cell infiltration (CD68,CD14,CD33,CD163) in tumor biopsies.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Functional HRD assay (optional)</measure>
    <time_frame>At baseline</time_frame>
    <description>Extra biopsy</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunological effects of PARP-1 inhibition (optional)</measure>
    <time_frame>Change From Baseline to 6 weeks and 12 weeks</time_frame>
    <description>Tests for T cell and APC functionality measured by the measurement of recall antigen responses and mixed lymphocyte cultures, respectively, the levels of regulatory T cells, activation markers on T cells and DC).</description>
  </other_outcome>
  <other_outcome>
    <measure>Predictive biomarkers for PD-L1 blocking in blood (optional)</measure>
    <time_frame>Change From Baseline to 6 weeks and 12 weeks</time_frame>
    <description>e.g. monocyticMDSC levels, DC levels, inhibitory marker expression, neutrophil-to-lymphocyte ratio, absolute lymphocyte count, T-cell reactivity during PD-L1 blocking, T-cell cytokine expression after SEB activation</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Endometrial Neoplasms</condition>
  <condition>Uterine Neoplasms</condition>
  <condition>Endometrium Cancer</condition>
  <arm_group>
    <arm_group_label>PARP inhibitor and Anti-PD-L1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PARP inhibitor and Anti-PD-L1</intervention_name>
    <description>olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks</description>
    <arm_group_label>PARP inhibitor and Anti-PD-L1</arm_group_label>
    <other_name>olaparib</other_name>
    <other_name>durvalumab</other_name>
    <other_name>PARP inhibitor</other_name>
    <other_name>Anti-PD-L1 Monoclonal Antibody</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  Histologically confirmed diagnosis of endometrial cancer or carcinosarcoma of the&#xD;
             endometrium.&#xD;
&#xD;
          -  Metastatic disease or locally advanced tumor not amenable to local therapy.&#xD;
&#xD;
          -  Documented progressive disease before enrolment.&#xD;
&#xD;
          -  Measurable lesions outside irradiated field or progressive measurable lesions in&#xD;
             irradiated area&#xD;
&#xD;
          -  Not eligible for hormonal therapy (because of negative hormone receptor/poor&#xD;
             differentiation, or after failure of hormonal therapy).&#xD;
&#xD;
          -  Previous failure of chemotherapy, or refusal to undergo chemotherapy or chemo-naive&#xD;
             patients not suitable for chemotherapy.&#xD;
&#xD;
          -  WHO performance 0-1&#xD;
&#xD;
          -  Adequate organ system function as measured within 28 days prior to administration of&#xD;
             study treatment, as defined below:&#xD;
&#xD;
               -  Haemoglobin ≥ 10.0 g/dL, with no blood transfusion in the past 28 days.&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Platelet count ≥ 100 x 109/L&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (not applicable&#xD;
                  to Gilbert's syndrome)&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT))&#xD;
                  / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤&#xD;
                  2.5 x ULN unless liver metastases are present in which case they must be ≤ 5x ULN&#xD;
&#xD;
               -  Patients must have creatinine clearance estimated of ≥51 mL/min estimated using&#xD;
                  the Cockcroft-Gault equation or 24 hr urine clearance.&#xD;
&#xD;
          -  Life expectancy of at least 16 weeks.&#xD;
&#xD;
          -  Measurable disease as defined by RECIST 1.1 criteria&#xD;
&#xD;
          -  Able to swallow and retain oral medication.&#xD;
&#xD;
          -  A female is eligible to enter and participate in this study if there is:&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product during the&#xD;
             last month or previous enrolment in the present study.&#xD;
&#xD;
          -  Any previous treatment with PARP inhibitor, including olaparib and/or any previous&#xD;
             treatment with a PD1 or PD-L1 inhibitor&#xD;
&#xD;
          -  History of another primary malignancy except for malignancy treated with curative&#xD;
             intent and with no known active disease ≥5 years before the first dose of&#xD;
             investigational product and of low potential risk for recurrence or adequately treated&#xD;
             non-melanoma skin cancer, lentigo maligna or carcinoma in situ.&#xD;
&#xD;
          -  History of leptomeningeal carcinomatosis, symptomatic uncontrolled brain metastases&#xD;
             (≤2mg/ day corticosteroids started ≥4 weeks prior to treatment is accepted) and spinal&#xD;
             cord compression (unless received definitive treatment and clinically stable for 28&#xD;
             days) .&#xD;
&#xD;
          -  Resting ECG with QTc &gt; 470 msec on 2 or more time points within a 24 hour period or&#xD;
             family history of long QT syndrome&#xD;
&#xD;
          -  Concomitant use of known strong or moderate CYP3A inhibitors and inducers.&#xD;
&#xD;
          -  Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the&#xD;
             exception of alopecia, vitiligo, and the laboratory values defined in the inclusion&#xD;
             criteria.&#xD;
&#xD;
          -  Current or prior use of immunosuppressive medication within 14 days before the first&#xD;
             dose of durvalumab (except intranasal and inhaled corticosteroids or systemic&#xD;
             prednisone ≤ 10 mg/day)&#xD;
&#xD;
          -  Major surgery ≤2 weeks of starting study treatment&#xD;
&#xD;
          -  History of active primary immunodeficiency&#xD;
&#xD;
          -  Active or prior documented autoimmune or inflammatory disorders, with exception of:&#xD;
             vitiligo or alopecia, hypothyroidism stable on hormone replacement, any chronic skin&#xD;
             condition that does not require systemic therapy, celiac disease controlled by diet&#xD;
             alone&#xD;
&#xD;
          -  Patients unable to swallow orally administered medication and patients with&#xD;
             gastrointestinal disorders likely to interfere with absorption of the study&#xD;
             medication.&#xD;
&#xD;
          -  Active infection including tuberculosis, hepatitis B/C and HIV&#xD;
&#xD;
          -  Patients with an expected or known hypersensitivity to olaparib or durvalumab or any&#xD;
             of the excipients of the products.&#xD;
&#xD;
          -  Previous allogenic bone marrow transplant or double umbilical cord blood&#xD;
             transplantation (dUCBT).&#xD;
&#xD;
          -  Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Amsterdam UMC, AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NKI-AVL</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RadboudMC</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>J.R. Kroep</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Poly (ADP-ribose) Polymerase Inhibitors</keyword>
  <keyword>Antibodies, Monoclonal</keyword>
  <keyword>Checkpoint Inhibitors</keyword>
  <keyword>olaparib</keyword>
  <keyword>durvalumab</keyword>
  <keyword>Anti-PD-L1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Poly(ADP-ribose) Polymerase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

